The latest OXB agreement will help advance the company’s CAR-T therapies and provide a “reliable, scalable manufacturing ...

OXB and Bristol Myers Squibb (BMS) are expanding a partnership regarding manufacture and supply of lentiviral vectors for BMS ...

OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmesMulti-year agreement with five-year ...

Whether it’s vaccines, protein production, or biotherapeutics, lentiviral vectors are increasingly being recognized for their central role as an enabling technology. The ability of lentiviral vectors ...

A new vector system known as lentiviral vectors can permanently integrate the gene into dividing and non-dividing cells. The capacity of lentiviral vectors to reliably integrate at various genomic ...

Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...

Lentiviral vectors are important gene delivery tools for cell and gene therapies, notably chimeric antigen receptor T-cell (CAR-T cell) therapies which have proven successful in treating a growing ...

Acquired from the human immunodeficiency virus (HIV), lentiviral vectors are one of the most practical and commonly used viral vectors. They provide the ability to transduce both non-dividing and ...

GERMANTOWN, Md. and PRAGUE, Czech Republic, May 18, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ORGS) (“Orgenesis”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT ...

The field of gene therapy has moved from promising scientific research to medical reality. With the potential to permanently correct genetic disorders with a one-time treatment, many gene therapies ...

Could CAR T Therapy, an innovative treatment for certain blood cancers, cause lymphoma? Reports from clinical trials and data released after product approval suggest that the treatment could trigger ...